VHLFA: New Page Name

Thursday 4th September BASIC AND MOLECULAR BIOLOGY OF vHL

09:00 a.m.    REGISTRATION

10:30 a.m.    OPENING

                   Chair: Patrick Maxwell and Thomas van Oveerem Hansen

10:40 a.m.    Peter Staller: The role of hypoxia-inducible factors in aggressive cancer behavior.

11:20 a.m    Patrick Maxwell: A critical role for VHL in glucose-sensing.

11:50 a.m    Rachel Giles: Tumor suppressor pVHL regulates kidney cell polarity 3D epithelial morphogenesis.

12:05 a.m    Norma Masson: Further studies of the pVHL-Collagen IV interaction.

12:20 a.m.    James Gnarra: The VHL E3 ubiquitin ligase complex and post-transcriptional regulation of hypoxia-induced gene expression.

12:35 a.m.    Eijiro Nakamura: Up regulation of JunB by the inactivation of von Hippel-Lindau tumor suppressor protein induces MMP-2 expression and enhances the invasive ability of renal cell carcinoma cells in vitro.

12:50 a.m.    Summary of the morning program.

12:55 a.m.    Messages

1:00 p.m.   Lunch

                  Chair: Stephen Lee and Lennart Friis-Hansen

2:00 p.m.    Stephen Lee: Understanding the HIF_ Oncogenic Pathway in Human Cancer.

2:30 p.m.    Xiaoqing Wu: The tumour suppressor von Hippel Lindau sensitizes cells to hypoxia via regulation of survivin.

2:45 p.m    Arnin Pause: The role of VHL in tumor suppression through regulation of ECM assembly.

3:00 p.m.   Ian Frew: Cooperative suppression of renal cysts and epididymal cystadenoma by the VHL and PTEN tumour suppressors.

3:15 p.m.   Maria F Czyzyk-Krezeska: Regulation on RNA Polymerase II by VHL and prolyl hydroxylases in kidney cancer.

3:30 p.m.   Coffee break

4:00 p.m.   Rachel Giles: Animal models in VHL.

4:30 p.m.   Ellen van Rooijen: The von Hippel-Lindau (VHL) tumor suppressor gene ortholog vhl regulates zebra fish hematopoisis.

4:50 p.m.   Tien Hsu: Up-regulation of FGF receptor signaling in VHL mutant cells – from flies to humans.

5:05 p.m.   Ding Xing-hua: Preliminary analysis of the gene expression profiles of central nervous system hemangioblastoma with cDNA microarray.

5:20 p.m.   Michael Wiesener: The lusyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia – insights into cellular transformation processes mediated by HIF-1.

5:35 p.m.   Eric Jonasch: Comparative assessment of Hemangioblastoma and Renal Cell Carcinoma Tissue Using laser Scanning Cytometry.

5:50 p.m.   Summary of the afternoon program

6:00 p.m.   Messages

7:30 p.m.    Get together buffet and visit to Viking ship museum

Friday 5th September CLINICAL AND GENETIC ASPECTS OF vHL

                  Chair: Eamonn Maher and Carsten Brandt

09:00 a.m.    Messages

9:05 a.m.    Eamonn Maher: Genetic aspects of tumourigenesis in VHL disease.

9:50 a.m.    J.C. Casali-da-Rocha: Identification of germline mutations in the VHL gene of families with the von Hippel-Lindau disease from Brazil.

10:05 a.m.    Mette Dandanell Nielsen: Characterization of germ-line mutations in the VHL gene in von Hippel Lindau disease patients from Denmark.

10.20 a.m    Ashok Pillai: Von Hippel Lindau Disease in Kerala, India: a clinical and genetic study.

10.35 a.m.    L. Andrews: Von Hippel Lindau Syndrome - a single institution’s 12 year experience

11:10 a.m.   Coffee break

                  Chair: Eamonn Maher and Mette Klarskov Andersen

11.15 a.m.    Hartmut Neumann: Familial Pheochromocytoma: Genetic Susceptibility, Clinical Diagnosis and Treatment Options.

11:55 a.m.    Julia R. Forman: Predicted mechanisms for renal cell carcinoma and pheochromocytoma in von Hippel-Lindau disease.

12:10 a.m.    Nicola Bradshaw: A Large Scottish VHL Kindred with Variable Penetrance.

12:25 a.m.    Lone Sunde: Reduced penetrance of c.407C>T, p.Ser65Leu in the VHL-gene.

12:40 a.m.    Sophie Giraud: Contribution of the dHPLC to the diagnosis of VHL somatic mosaicism.

12:55 a.m    Carsten A Brandt: vHL families without detected mutations in the VHL gene: is “Hereditary hemangioblastomatosis a separate entity”?

1:10 p.m.    Summary of the morning program.

1:15 p.m.   Lunch

                  Chair: Hartmut Neumann and Michael Kosteljanetz

2:10 p.m.   Alexander Vortmeyer: VHL disease - Evolution of Tumorigenesis in Human Tissues.

2:50 p.m.   V. Van Velthoven: Hemorrhagic Complications in Treatment of CNS Hemangioblastoma.

3:05 p.m.   Sven Gläsker: Essential and Pitfalls in Treatment of CNS Hemangioblastoma and von Hippel-Lindau Disease.

3:20 p.m.   Sven Gläsker: Nitric oxide as possible growth regulator of hemangioblastomas.

3:35 p.m.   Matthieu Peyre: Natural history of supratentorial hemangioblastomas in von Hippel-Lindau disease.

3:50 p.m.   Coffee break

4:15 p.m.   Marianne Wegener: Involvement of the eye in von Hippel-Lindau disease: update on diagnosis and therapy.

4:30 p.m   J.M. Corréas: Radiofrequency ablation of renal tumours in von Hippel-Lindau disease.

4:45 p.m.   H. Jeffrey Kim: Surgical Management of Endolymphatic Sac Tumors in von Hippel-Lindau Disease.

5:00 p.m.   Pascal Hammel: Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological and genetic features.

5:15 p.m.   Charline Ladroue: New germline PHD2 mutations in patients with congenital polycythemia.

5:30 p.m.   Betty Gardie: Unexpected truncating VHL germline mutation in a patient with polycythemia.

5:45 p.m.   Eric Jonasch:Updated Results for Ongoing Phase II Clinical Trial for Sunitinib in Patients with von Hippel Lindau Disease

6:00 p.m.    Summary of the afternoon program.

6:05 p.m.    Messages

7:30 p.m. Congress dinner

Saturday 6th September MANAGEMENT AND HANDLING OF vHL

                  Chair Paul M. Zeltzer and Lone Sunde

09:00 a.m.   Messages
9:05 a.m.   Paul M. Zeltzer: How the Internet has changed the classical doctor-patient relationship – or visit Genesis before you Google.

9:25 a.m.   Ying Hunang: A Three-Gene Expression Signature Model to Predict Clinical Outcome of Clear Cell Renal Carcinoma.

9:45 a.m.   Thoshinari Yamasaki: Existence of endothelial fenestrations in tumor microvasculature associated with VHL gene alteration is a potent predictive marker of anti-VEGF therapy in clear cell renal cell carcinoma in vivo.

10:05 a.m.   Marie Louise Mølgaard Poulsen: Prophylaxis in von Hippel-Lindau disease.

10:25 a.m.   Mette Bertelsen: An evaluation of Danish national clinical guidelines of von Hippel-Lindau (VHL) – Experience from a single institution.

10:45 a.m.   Coffee break

11:15 a.m.   Frauke Pelz : 20 years of VHL clinic in South Wales

11:35 a.m.   L. Andrews: Unmet information and support needs amongst individuals affected by VHL or MEN2A.

11:55 a.m   C.R.M. Lammens: The psychosocial impact of von Hippel-Lindau Disease

12:15 a.m   Summary and closing remarks.

12:30 p.m.   Lunch

13:30 p.m.   vHL leadership meeting

Conference 2008 Roskilde

Agenda